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INTRODUCTION
Uncontrolled hyper thyroidism has a myriad of
presentations. Classically, symptoms include weight loss,
tremor, palpitations, shortness of breath, diarrhea, anxiety,
and heat intolerance. A rare manifestation of hyperthyroidism is thyrotoxic periodic paralysis (TPP). Periodic
paralysis is a musculoskeletal channelopathy manifested
by episodes of painless muscle weakness often
precipitated by heav y exercise, fasting, or high
carbohydrate meals. Although classically associated with
painless weakness; cramping, myalgias, and stiffness can
also occur prior to the episodes as prodromal symptoms.
Neurologic examination during an attack typically
demonstrates proximal more than distal muscle
weakness, and the upper extremities are more commonly
affected than the lower extremities.1-4 Consciousness and
sensation are preserved, and respiratory muscle
involvement is exceedingly rare. Episodes of weakness
can last from a few hours up to 72 hours with intermittent
recovery between attacks. Patients most often have
diminished deep tendon reflexes, but reflexes may be
preserved in some cases. We present a case of TPP,
discuss the differential diagnosis of periodic paralysis, and
review the pathophysiology and management of TPP.

CASE DESCRIPTION
A 39-year-old man with a past medical history of
hyperthyroidism presented with 5 days of progressive,
bilateral leg weakness and neck pain. On the day of
presentation, the patient was unable to walk normally. He
reported a 40-pound weight loss over the 3 months prior
to admission. He had been diagnosed with a “thyroid
problem” five years ago in Taiwan after having a similar
episode, but he had stopped taking the prescribed
medication when he arrived in the United States two
years ago. He never received radioactive iodine. He
endorsed palpitations, dizziness, headache, and
diaphoresis. He denied chest pain, shortness of breath,
nausea, vomiting, and diarrhea. On exam, he was
diaphoretic, but awake, alert and oriented without
distress. His pupils were equal, round, and reactive
without lid lag or proptosis, although, on repeat
examination there was concern for lid retraction in the
left eye. There was mild thyromegaly and he was
tachycardic with a grade 2/6 holosystolic murmur loudest
in the left sternal border. He had no sensory deficits, but

2/5 strength in hip and knee flexion and extension
bilaterally, and 3/5 strength in plantar flexion and
extension bilaterally. ECG showed sinus tachycardia at a
rate of 106 beats per minute with bigeminy and
nonspecific T wave changes. Labs notable for a potassium
of 1.7 mmol/L (reference range 3.4-4.5 mmol/L),
magnesium of 1.3 mEq/L (reference range 1.3 – 2.1
mEq/L), thyrotropin <0.02 mIU/L (reference range 2.5-4.5
mIU/L), free T4 >7.8 ng/dL (reference range 0.7 – 1.7 ng/
dL), and free T3 of 23.3 pg/mL (reference range 2.0 – 4.4
pg/mL). CT scan of the orbits without the administration
of intravenous contrast showed no extraocular muscle
involvement or proptosis. Ultrasound of the thyroid
showed heterogenous texture and innumerable nodules
in both lobes suggestive of thyroiditis.
Endocrinology was consulted for hyperthyroidism, and
recommended methimazole 30mg daily in addition to
potassium replacement and propranolol 40mg.
Ophthalmology was consulted and there was no
evidence of thyroid optic neuropathy, but they did
comment on possible lid retraction in the left eye and
enophthalmos in the right eye. The patient was admitted
to the ICU for frequent laboratory checks and close
monitoring. About 6 hours following potassium
replacement, antithyroid therapy and beta blockade, the
patient’s strength and potassium improved.

DIFFERENTIAL DIAGNOSIS
Causes of potassium loss can be classified as renal or
nonrenal, or separately by transcellular shift, one of the
causes of which is periodic paralysis. Causes of periodic
paralysis include hyperkalemia, hypokalemia, familial
hypokalemic periodic paralysis, or Andersen syndrome,
an autosomal dominant inherited defect of the inward
rectifying potassium channel associated with short
stature, hypertelorism, clinodactyly, and micrognathia.5

OUTCOME AND FOLLOW UP
Following potassium replacement, the patient was
discharged on methimazole 30mg daily without any
neurologic symptoms. Despite having been scheduled
for an appointment with Endocrinology, the patient was
lost to follow-up.
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DISCUSSION

KEY POINTS

TPP is a rare, potentially life-threatening complication of
hyperthyroidism. TPP occurs in about two percent of
Asian patients with hyperthyroidism compared to 0.1 to
0.2 percent of the general population.3 Despite the fact
that hyperthyroidism occurs more frequently in women,
over 95% of TPP cases occur in men.6 Disease onset
typically occurs between ages 20 and 50 years, whereas
familial hypokalemic periodic paralysis and Andersen
syndrome occur in patients typically under the age of 20
years. 7- 8 The pathophysiology of TPP relates to
hypokalemia: thyroid hormone increases sodiumpotassium ATPase activity on skeletal muscle, forcing
potassium to the intracellular space. The resultant
hyperpolarized muscle membrane reduces the
excitability of the muscle tissue. Excess thyroid hormone
also increases insulin resistance and beta-adrenergic
responsiveness. Insulin and epinephrine both enhance
sodium-potassium ATPase activity, further forcing
potassium into the cell.7-8

Thyrotoxic periodic paralysis is a rare complication of
hyperthyroidism consisting of painless muscle weakness
and hypokalemia. Acute management involves
potassium replacement and propranolol, while long
term prevention requires methimazole to maintain
euthyroid status.

The management of TPP consists of potassium repletion
and normalization of thyroid hormone. Patients are
typically hospitalized and monitored on telemetry due to
the risk of cardiac arrhythmias in the setting of labile
potassium levels. Correction of potassium provides the
mainstay of treatment, and it is important to check
potassium levels frequently due to the risk of rebound
hyperkalemia.9 Intravenous potassium provides more
rapid normalization of potassium levels and is the
recommended treatment modality. 10 As always with
hypokalemic patients, concurrent repletion of hypomagnesemia, if present, is recommended as well. For patients
who are found to be refractory to potassium repletion
monotherapy or who are deemed to be at high risk of
complications due to arrhythmia, concurrent therapy
with propranolol, methimazole, or both may be utilized
as well. Preventative therapy requires proper monitoring
of TSH with the goal of sustaining a euthyroid state with
methimazole. Empiric potassium repletion has not been
shown to be an effective deterrent.7
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